Shares of Puma Biotechnology, Inc. PBYI have rallied 24% in the past three months against the industry’s decline of 9.7%. The company’s sole marketed product, Nerlynx (neratinib), is approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback